浙江大学发表最新Cell子刊论文

Core Viewpoint - The research identifies a class of micropeptides related to hepatocellular carcinoma (HCC) and reveals their regulatory mechanisms on mitochondrial RNA processing, providing new insights for cancer diagnosis and treatment [3][8]. Group 1: Research Findings - A new study published in Molecular Cell describes micropeptides associated with HCC and their role in modulating mitochondrial RNA processing machinery [3]. - The research team utilized a novel ultrafiltration tandem mass spectrometry method to identify a significant number of micropeptides in clinical HCC samples [4]. - One specific micropeptide, mitochondrial RNase P inhibitory peptide (MRPIP), derived from long non-coding RNA (lncRNA), inhibits the progression of HCC by regulating mitochondrial RNA processing [4][5]. Group 2: Mechanism of Action - MRPIP interacts with the R25 residue of HSD17B10, preventing the assembly of the mitochondrial RNase P (mtRNase P) complex, which disrupts HSD17B10 oligomerization and subsequent formation of the HSD17B10-TRMT10C subcomplex [5]. - This disruption leads to disturbances in post-transcriptional RNA processing, translation, and energy generation in mitochondria, thereby inhibiting cancer progression [5]. Group 3: Implications for Treatment - The research generated a functional peptide of 20 amino acids from the MRPIP sequence, which significantly inhibits the progression of HCC both in vitro and in vivo [6].